Asthika Goonewardene
Stock Analyst at Truist Securities
(2.08)
# 3,042
Out of 5,237 analysts
83
Total ratings
40.74%
Success rate
-5.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Buy | $40 | $24.03 | +66.46% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $29.02 | +48.17% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $26.18 | +83.35% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $133.52 | +8.60% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $24.86 | +56.88% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $14.23 | +602.74% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $144.15 | -31.32% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $49.71 | -1.43% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $93.34 | +66.06% | 3 | Jun 3, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $88 → $71 | $25.58 | +177.56% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $2.28 | +338.60% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.58 | +532.91% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $3.70 | +305.41% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $18.66 | +87.57% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $39.31 | +281.58% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.87 | +39.37% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $2.03 | +835.96% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $8.17 | +5,187.64% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.13 | +1,376.01% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $0.77 | +7,692.21% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $9.79 | +1,739.55% | 4 | Aug 23, 2022 |
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $24.03
Upside: +66.46%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $29.02
Upside: +48.17%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $26.18
Upside: +83.35%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $133.52
Upside: +8.60%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $24.86
Upside: +56.88%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $14.23
Upside: +602.74%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $144.15
Upside: -31.32%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $49.71
Upside: -1.43%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $93.34
Upside: +66.06%
Legend Biotech
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $25.58
Upside: +177.56%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $2.28
Upside: +338.60%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.58
Upside: +532.91%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.70
Upside: +305.41%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $18.66
Upside: +87.57%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $39.31
Upside: +281.58%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.87
Upside: +39.37%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $2.03
Upside: +835.96%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $8.17
Upside: +5,187.64%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.13
Upside: +1,376.01%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $0.77
Upside: +7,692.21%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $9.79
Upside: +1,739.55%